Bolivia vs Ecuador: Average cost of drugs for extensively drug-resistant tuberculosis
Bolivia
753 constant 2022 US$
in 2024
Ecuador
451 constant 2022 US$
in 2024
Bolivia rank
48th
Ecuador rank
50th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Bolivia
- Ecuador
How they compare
Bolivia currently reports 753 constant 2022 US$ against 451 constant 2022 US$ in Ecuador, a difference of 302 constant 2022 US$.
That makes Bolivia's figure about 1.7 times Ecuador's.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Ecuador ahead.
Bolivia ranks 48th and Ecuador ranks 50th of 56 countries.
Bolivia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bolivia | Ecuador | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 9,977 constant 2022 US$ | 6,927 constant 2022 US$ | 3,050 constant 2022 US$ | Bolivia |
| 2020s | 8,250 constant 2022 US$ | 768 constant 2022 US$ | 7,482 constant 2022 US$ | Bolivia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Bolivia or Ecuador?
- Bolivia, at 753 constant 2022 US$ against 451 constant 2022 US$ in Ecuador as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Bolivia and Ecuador?
- 302 constant 2022 US$, with Bolivia ahead.
- How many years of comparable data are there for Bolivia and Ecuador?
- 5 years are reported by both, from 2017 to 2024.
- How do Bolivia and Ecuador rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Bolivia ranks 48th and Ecuador ranks 50th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.